The most frequently amplified genes in ALM patients were CCND1 (57.6%), MYC (48.5%), CDK4 (39.4%), FGFR1 (33.3%), CCND2 (33.3%), EGFR (30.3%), ERBB2 (27.3%), and MDM2 (24.2%) (Figure 1A). This evidence concerns the gene FGFR1 and acral lentiginous melanoma.